We are on a mission to exponentially improve the number of quality years for patients.
We are building upon our leadership team’s proven track record of designing and developing innovative small molecules, that aim to overcome the limitations of existing cancer therapies.
The BlossomHill Way, is our intentional, chemistry-based approach that has yielded multiple clinical-stage programs with the potential to address significant unmet medical needs in cancer treatment.
We are deeply committed to those who matter most: patients.
Join us to help redefine the treatment of cancer by advancing the next generation of targeted therapies.
Latest News
-
September 15, 2026
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
Read More -
September 3, 2026
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
Read More -
September 1, 2026
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
Read More